![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: STT3B |
Gene summary for STT3B |
![]() |
Gene information | Species | Human | Gene symbol | STT3B | Gene ID | 201595 |
Gene name | STT3 oligosaccharyltransferase complex catalytic subunit B | |
Gene Alias | CDG1X | |
Cytomap | 3p23 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8TCJ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
201595 | STT3B | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.02e-09 | -5.90e-01 | 0.0155 |
201595 | STT3B | HTA11_696_2000001011 | Human | Colorectum | AD | 3.42e-13 | -5.05e-01 | -0.1464 |
201595 | STT3B | HTA11_866_2000001011 | Human | Colorectum | AD | 3.35e-09 | -4.18e-01 | -0.1001 |
201595 | STT3B | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.41e-09 | -3.95e-01 | 0.0674 |
201595 | STT3B | A015-C-203 | Human | Colorectum | FAP | 7.71e-24 | -2.15e-01 | -0.1294 |
201595 | STT3B | A015-C-204 | Human | Colorectum | FAP | 3.90e-02 | -1.54e-01 | -0.0228 |
201595 | STT3B | A002-C-201 | Human | Colorectum | FAP | 4.30e-09 | -2.30e-01 | 0.0324 |
201595 | STT3B | A001-C-119 | Human | Colorectum | FAP | 1.73e-02 | -2.98e-01 | -0.1557 |
201595 | STT3B | A001-C-108 | Human | Colorectum | FAP | 2.59e-10 | -3.78e-02 | -0.0272 |
201595 | STT3B | A002-C-205 | Human | Colorectum | FAP | 1.09e-16 | -2.72e-01 | -0.1236 |
201595 | STT3B | A015-C-006 | Human | Colorectum | FAP | 2.93e-11 | -4.05e-01 | -0.0994 |
201595 | STT3B | A015-C-106 | Human | Colorectum | FAP | 5.48e-07 | -1.11e-01 | -0.0511 |
201595 | STT3B | A002-C-114 | Human | Colorectum | FAP | 1.11e-12 | -4.04e-01 | -0.1561 |
201595 | STT3B | A015-C-104 | Human | Colorectum | FAP | 2.75e-26 | -3.44e-01 | -0.1899 |
201595 | STT3B | A001-C-014 | Human | Colorectum | FAP | 5.45e-08 | -4.41e-02 | 0.0135 |
201595 | STT3B | A002-C-016 | Human | Colorectum | FAP | 8.33e-17 | -1.57e-01 | 0.0521 |
201595 | STT3B | A015-C-002 | Human | Colorectum | FAP | 1.82e-07 | -1.90e-01 | -0.0763 |
201595 | STT3B | A001-C-203 | Human | Colorectum | FAP | 1.55e-08 | -2.41e-02 | -0.0481 |
201595 | STT3B | A002-C-116 | Human | Colorectum | FAP | 4.53e-30 | -3.03e-01 | -0.0452 |
201595 | STT3B | A014-C-008 | Human | Colorectum | FAP | 4.25e-09 | -2.99e-01 | -0.191 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004316125 | Oral cavity | EOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 92/2218 | 412/18723 | 9.87e-10 | 6.96e-08 | 92 |
GO:003650321 | Oral cavity | EOLP | ERAD pathway | 25/2218 | 107/18723 | 6.07e-04 | 5.08e-03 | 25 |
GO:003043321 | Oral cavity | EOLP | ubiquitin-dependent ERAD pathway | 20/2218 | 85/18723 | 1.87e-03 | 1.21e-02 | 20 |
GO:001827921 | Oral cavity | EOLP | protein N-linked glycosylation via asparagine | 8/2218 | 23/18723 | 3.63e-03 | 2.04e-02 | 8 |
GO:001819621 | Oral cavity | EOLP | peptidyl-asparagine modification | 8/2218 | 24/18723 | 4.89e-03 | 2.61e-02 | 8 |
GO:001049831 | Oral cavity | NEOLP | proteasomal protein catabolic process | 103/2005 | 490/18723 | 1.08e-11 | 1.65e-09 | 103 |
GO:004316131 | Oral cavity | NEOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 89/2005 | 412/18723 | 6.27e-11 | 7.44e-09 | 89 |
GO:003497632 | Oral cavity | NEOLP | response to endoplasmic reticulum stress | 56/2005 | 256/18723 | 1.39e-07 | 4.84e-06 | 56 |
GO:003596632 | Oral cavity | NEOLP | response to topologically incorrect protein | 38/2005 | 159/18723 | 1.46e-06 | 3.68e-05 | 38 |
GO:000698632 | Oral cavity | NEOLP | response to unfolded protein | 34/2005 | 137/18723 | 2.08e-06 | 4.87e-05 | 34 |
GO:001049818 | Prostate | BPH | proteasomal protein catabolic process | 153/3107 | 490/18723 | 4.13e-16 | 7.51e-14 | 153 |
GO:003497618 | Prostate | BPH | response to endoplasmic reticulum stress | 95/3107 | 256/18723 | 1.54e-15 | 2.52e-13 | 95 |
GO:000698618 | Prostate | BPH | response to unfolded protein | 61/3107 | 137/18723 | 1.40e-14 | 1.80e-12 | 61 |
GO:003596618 | Prostate | BPH | response to topologically incorrect protein | 66/3107 | 159/18723 | 7.35e-14 | 7.98e-12 | 66 |
GO:004316118 | Prostate | BPH | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3107 | 412/18723 | 3.84e-13 | 3.60e-11 | 127 |
GO:00182797 | Prostate | BPH | protein N-linked glycosylation via asparagine | 13/3107 | 23/18723 | 1.54e-05 | 1.95e-04 | 13 |
GO:00181967 | Prostate | BPH | peptidyl-asparagine modification | 13/3107 | 24/18723 | 2.85e-05 | 3.32e-04 | 13 |
GO:00365034 | Prostate | BPH | ERAD pathway | 35/3107 | 107/18723 | 3.17e-05 | 3.60e-04 | 35 |
GO:00304333 | Prostate | BPH | ubiquitin-dependent ERAD pathway | 29/3107 | 85/18723 | 6.22e-05 | 6.23e-04 | 29 |
GO:00064874 | Prostate | BPH | protein N-linked glycosylation | 21/3107 | 65/18723 | 1.37e-03 | 8.19e-03 | 21 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04141 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
hsa00510 | Colorectum | AD | N-Glycan biosynthesis | 21/2092 | 53/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 21 |
hsa041411 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
hsa005101 | Colorectum | AD | N-Glycan biosynthesis | 21/2092 | 53/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 21 |
hsa041418 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
hsa041419 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa0414114 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
hsa005104 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa005134 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0414115 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
hsa0051011 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa0051311 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STT3B | SNV | Missense_Mutation | novel | c.2123G>A | p.Gly708Glu | p.G708E | Q8TCJ2 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
STT3B | SNV | Missense_Mutation | novel | c.1022G>A | p.Arg341Lys | p.R341K | Q8TCJ2 | protein_coding | tolerated(0.53) | benign(0.003) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
STT3B | SNV | Missense_Mutation | c.1549G>A | p.Val517Met | p.V517M | Q8TCJ2 | protein_coding | tolerated(0.1) | benign(0.07) | TCGA-D8-A1JL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STT3B | SNV | Missense_Mutation | c.1249G>A | p.Asp417Asn | p.D417N | Q8TCJ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
STT3B | insertion | In_Frame_Ins | novel | c.2032_2033insATT | p.Met678delinsAsnLeu | p.M678delinsNL | Q8TCJ2 | protein_coding | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
STT3B | SNV | Missense_Mutation | c.2224C>T | p.Arg742Cys | p.R742C | Q8TCJ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9V3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
STT3B | SNV | Missense_Mutation | c.1747G>T | p.Asp583Tyr | p.D583Y | Q8TCJ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
STT3B | SNV | Missense_Mutation | c.986N>T | p.Ala329Val | p.A329V | Q8TCJ2 | protein_coding | tolerated(0.34) | benign(0.015) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
STT3B | SNV | Missense_Mutation | novel | c.2139N>T | p.Leu713Phe | p.L713F | Q8TCJ2 | protein_coding | tolerated(0.27) | benign(0.2) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
STT3B | SNV | Missense_Mutation | c.1026N>G | p.Asp342Glu | p.D342E | Q8TCJ2 | protein_coding | tolerated(0.15) | benign(0.006) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |